RemeGen Co

RemeGen Co EBITDA Margin

The EBITDA Margin of RemeGen Co (688331.SS) as of Oct 26, 2026 is 22.19 %. In the previous year, EBITDA Margin was -71.72 % — a change of -130.94% (higher).

EBITDA Margin

22.19 %

YoY

-130.94%

Last updated:

EBITDA Margin of RemeGen Co is 2025 22.19 % . EBITDA Margin of RemeGen Co was 2024 -71.72 % . It decreases by -130.94% higher compared to the previous year.

The RemeGen Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-2,147.99 CNY
Jan 1, 2019
-15,705.85 CNY
Jan 1, 2020
145,701.26 CNY
Jan 1, 2021
11.44 CNY
Jan 1, 2022
-111.25 CNY
Jan 1, 2023
-122.32 CNY
Jan 1, 2024
-71.72 CNY
Jan 1, 2025
22.19 CNY
The RemeGen Co EBITDA Margin history
YEAREBITDA MarginYoY
22.19 %-130.94%
-71.72 %-41.37%
-122.32 %+9.95%
-111.25 %-1,072.83%
11.44 %-99.99%
145,701.26 %-1,027.69%
-15,705.85 %+631.19%
-2,147.99 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

EBITDA Margin of RemeGen Co is 22.19 % in 2025.

EBITDA Margin of RemeGen Co changed from -71.72 % to 22.19 %, representing a -130.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's RemeGen Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — RemeGen Co

All Key Metrics — RemeGen Co